Want to see JP:197A full AI Analyst Report?
Top Page
Tauns Laboratories, Inc.
(197A)
Select Model
Select Model
Rating:70Outperform
Price Target:
¥547.00
▲(7.47% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily supported by attractive valuation (low P/E and high dividend yield) and generally positive technical momentum. These positives are balanced by financial-performance risks, especially volatile cash generation (negative in 2026) alongside materially higher leverage, which increases sensitivity to any earnings or working-capital swings.
Positive Factors
Strong Profitability
Sustained gross and operating profitability, together with a substantially higher net margin, indicates strong earnings capacity. This provides internal funding potential and resilience, although operating-margin trends should continue to be monitored.
Negative Factors
Volatile Cash Generation
Repeated swings between positive and negative operating cash flow weaken earnings quality and make funding needs harder to predict. If volatility persists, the company may rely more heavily on debt or working-capital management.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Sustained gross and operating profitability, together with a substantially higher net margin, indicates strong earnings capacity. This provides internal funding potential and resilience, although operating-margin trends should continue to be monitored.
Read all positive factors
Tauns Laboratories, Inc. (197A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥53.67B
Dividend Yield5.5%
Average Volume (3M)400.80K
Price to Earnings (P/E)9.7
Beta (1Y)0.32
Revenue Growth-22.86%
EPS Growth-15.94%
CountryJP
Employees271
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)20.24
Shares Outstanding106,702,350
10 Day Avg. Volume355,040
30 Day Avg. Volume400,796
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)2.55
Price to Sales (P/S)3.45
P/FCF Ratio-7.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.43
Revenue Forecast (FY)¥17.78B
Tauns Laboratories, Inc. Business Overview & Revenue Model
Company Description
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an ex...
Tauns Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.68B | 14.37B | 18.63B | 18.43B | 15.67B | 17.46B |
| Gross Profit | 7.13B | 8.22B | 12.33B | 12.50B | 8.79B | 14.29B |
| EBITDA | 3.37B | 5.33B | 9.02B | 8.65B | 5.32B | 8.55B |
| Net Income | 2.11B | 5.50B | 6.32B | 5.77B | 3.03B | 4.48B |
Balance Sheet | ||||||
| Total Assets | 41.45B | 44.62B | 36.52B | 29.26B | 18.81B | 20.88B |
| Cash, Cash Equivalents and Short-Term Investments | 5.89B | 3.56B | 9.27B | 9.42B | 1.24B | 6.35B |
| Total Debt | 21.71B | 21.26B | 14.42B | 9.54B | 6.47B | 4.90B |
| Total Liabilities | 25.14B | 25.20B | 19.10B | 15.59B | 10.32B | 13.52B |
| Stockholders Equity | 16.31B | 19.42B | 17.42B | 13.67B | 8.49B | 7.36B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -6.61B | 2.14B | 5.97B | -4.32B | 8.39B |
| Operating Cash Flow | 0.00 | -2.83B | 6.82B | 9.94B | -3.16B | 10.69B |
| Investing Cash Flow | 0.00 | -6.18B | -9.26B | -4.11B | -1.62B | -2.68B |
| Financing Cash Flow | 0.00 | 3.30B | 2.28B | 2.36B | -330.20M | -3.66B |
Tauns Laboratories, Inc. Technical Analysis
Positive
509.00
Price Trends
477.85
Positive
480.12
Positive
493.65
Positive
Market Momentum
8.55
Negative
64.56
Neutral
74.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:197A, the sentiment is Positive. The current price of 509 is above the 20-day moving average (MA) of 486.00, above the 50-day MA of 477.85, and above the 200-day MA of 493.65, indicating a bullish trend. The MACD of 8.55 indicates Negative momentum. The RSI at 64.56 is Neutral, neither overbought nor oversold. The STOCH value of 74.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:197A.
Tauns Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥53.67B | 9.72 | ― | 5.09% | -22.86% | -15.94% | |
64 Neutral | ¥58.20B | 10.74 | ― | 2.79% | 1.72% | 6.07% | |
57 Neutral | ¥76.06B | 21.31 | ― | 2.28% | 2.94% | 57.05% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥65.84B | 80.80 | ― | 2.71% | 23.75% | ― | |
52 Neutral | ¥61.59B | 31.14 | ― | 4.71% | -4.71% | -78.91% |
* General Sector Average
JP:197A
Tauns Laboratories, Inc.
509.00
-29.50
-5.48%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,385.00
-247.36
-15.15%
JP:4549
Eiken Chemical Co., Ltd.
2,298.00
-87.73
-3.68%
JP:4552
JCR Pharmaceuticals Co., Ltd.
543.00
-58.14
-9.67%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,177.00
-289.11
-19.72%
JP:368A
Kitazato Corporation
1,500.00
9.18
0.62%
Tauns Laboratories, Inc. Corporate Events
Tauns Laboratories’ Profit Slides on Lower Sales as Cash Flow Turns Negative
Aug 13, 2026
Tauns Laboratories reported FY2026 net sales of ¥14.37 billion, down 22.9% year on year, with operating income halving to ¥4.20 billion and ordinary income falling 51.9%, while net income declined a milder 13% to ¥5.50 billion as pr...
Tauns Laboratories Books ¥3.9 Billion Government Subsidy as Special Gain
Aug 13, 2026
Tauns Laboratories has booked a special gain of ¥3,949 million in the fourth quarter of the fiscal year ending June 30, 2026, after receiving final approval for a government subsidy under Japan’s “Subsidy Program for Promoting Dom...
Tauns Laboratories Corrects Presentation of Operating Income Forecast Without Changing Outlook
Jul 24, 2026
Tauns Laboratories has issued a correction to its recently updated mid-term management plan, clarifying the way it presents its full-year operating income forecast for the fiscal year ending June 30, 2026. The company confirmed that the forecast r...
Tauns Laboratories Revamps Mid-Term Plan With Strong Growth Targets
Jul 15, 2026
Tauns Laboratories has updated its mid-term management plan, shifting the covered period to the fiscal years ending June 2027 through June 2031 in response to changes in the business environment and the progress of its existing strategy. The new p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.